Status:
UNKNOWN
Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea
Lead Sponsor:
Yonsei University
Conditions:
Atrophic Gastritis
Eligibility:
FEMALE
19+ years
Brief Summary
It is well-known that atrophic gastritis is a major risk factor for gastric cancer, which leads to variations in the serum levels of gastrin, pepsinogen (PG) I, and PGII. We want to assess the effects...
Eligibility Criteria
Inclusion
- over 19 years
- the patients who have gastrointestinal discomfort or get esophagogastroduodenoscopy (EGD) for health check up
- the patients who got the procedure, endoscopic submucosal resection (ESD) for early gastric cancer
Exclusion
- gastrectomy history
- advanced gastric cancer (impossible to get the gastrectomy)
- Helicobacter eradication history
- the patients who have chronic disease
- cancer patients except gastric cancer within 6 months
- who cannot perform this study according to research's decision
- who have bleeding tendency (ex. taking antiplatelet agent, low platelet count or abnormal coagulation time)
Key Trial Info
Start Date :
December 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT02184910
Start Date
December 1 2013
End Date
December 1 2023
Last Update
March 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance hospital
Seoul, South Korea, 120-752